Market Cap | 101.99M | P/E | - | EPS this Y | 45.30% | Ern Qtrly Grth | - |
Income | -81.45M | Forward P/E | -1.16 | EPS next Y | -0.80% | 50D Avg Chg | 4.00% |
Sales | 80.03M | PEG | 0.31 | EPS past 5Y | - | 200D Avg Chg | -11.00% |
Dividend | N/A | Price/Book | 0.53 | EPS next 5Y | -13.70% | 52W High Chg | -61.00% |
Recommedations | 2.00 | Quick Ratio | 2.93 | Shares Outstanding | 65.94M | 52W Low Chg | 26.00% |
Insider Own | 24.10% | ROA | -23.28% | Shares Float | 28.85M | Beta | 1.92 |
Inst Own | 60.13% | ROE | -56.49% | Shares Shorted/Prior | 2.27M/1.98M | Price | 2.18 |
Gross Margin | 27.76% | Profit Margin | -101.78% | Avg. Volume | 239,790 | Target Price | 7.05 |
Oper. Margin | -74.81% | Earnings Date | Nov 5 | Volume | 213,449 | Change | -3.11% |
Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.
HC Wainwright & Co. | Buy | Aug 19, 24 |
BTIG | Buy | Aug 16, 24 |
Needham | Buy | Aug 16, 24 |
Needham | Buy | Jun 21, 24 |
Needham | Buy | May 9, 24 |
Lake Street | Buy | Apr 30, 24 |
Needham | Buy | Apr 11, 24 |
Needham | Buy | Feb 29, 24 |
Needham | Buy | Jan 5, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Chen Richard | Chief Medical Office.. Chief Medical Officer and EVP | Dec 15 | Sell | 1.47 | 4,708 | 6,921 | 129,396 | 12/19/23 |
Tachibana Aaron | CFO and COO CFO and COO | Dec 15 | Sell | 1.47 | 6,747 | 9,918 | 185,237 | 12/19/23 |
Moore Stephen Michael | General Counsel General Counsel | Dec 15 | Sell | 1.47 | 1,476 | 2,170 | 76,920 | 12/19/23 |
Moore Stephen Michael | General Counsel General Counsel | Nov 16 | Sell | 1.04 | 1,722 | 1,791 | 78,396 | 11/20/23 |
Tachibana Aaron | CFO and COO CFO and COO | Nov 16 | Sell | 1.04 | 1,344 | 1,398 | 191,984 | 11/20/23 |
Chen Richard | Chief Medical Office.. Chief Medical Officer and EVP | Nov 16 | Sell | 1.04 | 940 | 978 | 124,104 | 11/20/23 |
Hall Christopher M | President and CEO President and CEO | Nov 01 | Sell | 0.93 | 20,459 | 19,027 | 204,541 | 11/03/23 |
Chen Richard | Chief Medical Office.. Chief Medical Officer and EVP | May 17 | Sell | 1.98 | 971 | 1,923 | 130,346 | 05/19/23 |
Tachibana Aaron | CFO and COO CFO and COO | Mar 17 | Sell | 2.83 | 3,945 | 11,164 | 202,283 | 03/21/23 |
Chen Richard | Chief Medical Office.. Chief Medical Officer and EVP | Mar 17 | Sell | 2.83 | 1,314 | 3,719 | 131,317 | 03/21/23 |
Tachibana Aaron | Chief Financial Offi.. Chief Financial Officer | Jan 31 | Sell | 2.20 | 767 | 1,687 | 206,228 | 02/02/23 |
Tachibana Aaron | Chief Financial Offi.. Chief Financial Officer | Dec 02 | Sell | 2.60 | 4,360 | 11,336 | 218,015 | 12/06/22 |
Chen Richard | Chief Medical Office.. Chief Medical Officer | Dec 02 | Sell | 2.60 | 440 | 1,144 | 142,120 | 12/06/22 |
Moore Stephen Michael | General Counsel General Counsel | Nov 16 | Sell | 2.71 | 2,045 | 5,542 | 90,440 | 11/18/22 |
Tachibana Aaron | Chief Financial Offi.. Chief Financial Officer | Nov 16 | Sell | 2.71 | 1,294 | 3,507 | 222,375 | 11/18/22 |
Chen Richard | Chief Medical Office.. Chief Medical Officer | Sep 20 | Sell | 3.48 | 1,581 | 5,502 | 143,855 | 09/22/22 |
Tachibana Aaron | Chief Financial Offi.. Chief Financial Officer | Sep 20 | Sell | 3.48 | 3,474 | 12,090 | 223,669 | 09/22/22 |
Chen Richard | Chief Medical Office.. Chief Medical Officer | Sep 02 | Sell | 3.33 | 420 | 1,399 | 145,436 | 09/08/22 |
Chen Richard | Chief Medical Office.. Chief Medical Officer | Jul 28 | Sell | 3.91 | 632 | 2,471 | 145,856 | 08/01/22 |
Tachibana Aaron | Chief Financial Offi.. Chief Financial Officer | Jul 28 | Sell | 3.91 | 632 | 2,471 | 231,311 | 08/01/22 |
Chen Richard | Chief Medical Office.. Chief Medical Officer | Jun 17 | Sell | 3.29 | 1,565 | 5,149 | 146,488 | 06/21/22 |
Tachibana Aaron | Chief Financial Offi.. Chief Financial Officer | Jun 17 | Sell | 3.29 | 3,440 | 11,318 | 231,943 | 06/21/22 |
Moore Stephen Michael | General Counsel General Counsel | Jun 15 | Sell | 3.24 | 1,832 | 5,936 | 73,885 | 06/17/22 |
Tachibana Aaron | Chief Financial Offi.. Chief Financial Officer | Jun 15 | Sell | 3.24 | 6,818 | 22,090 | 235,383 | 06/17/22 |
Tachibana Aaron | Chief Financial Offi.. Chief Financial Officer | Jun 02 | Sell | 3.59 | 4,187 | 15,031 | 242,201 | 06/06/22 |
Chen Richard | Chief Medical Office.. Chief Medical Officer | Jun 02 | Sell | 3.59 | 421 | 1,511 | 154,871 | 06/06/22 |
Tachibana Aaron | Chief Financial Offi.. Chief Financial Officer | May 16 | Sell | 4.86 | 1,286 | 6,250 | 246,388 | 05/18/22 |
West John Stephen | President and CEO President and CEO | May 16 | Sell | 4.86 | 2,408 | 11,703 | 382,444 | 05/18/22 |
Moore Stephen Michael | General Counsel General Counsel | May 16 | Sell | 4.86 | 664 | 3,227 | 75,717 | 05/18/22 |
Chen Richard | Chief Medical Office.. Chief Medical Officer | May 16 | Sell | 4.86 | 1,286 | 6,250 | 155,830 | 05/18/22 |
Moore Stephen Michael | General Counsel General Counsel | May 02 | Sell | 5.53 | 5,733 | 31,703 | 76,381 | 05/04/22 |
West John Stephen | President and CEO President and CEO | Apr 20 | Option | 1.84 | 45,061 | 82,912 | 384,852 | 04/22/22 |
West John Stephen | President and CEO President and CEO | Apr 13 | Option | 1.84 | 64,430 | 118,551 | 404,221 | 04/15/22 |
Lightspeed Venture Partners Se... | Other Other | Mar 02 | Buy | 10.06 | 314,750 | 3,166,385 | 4,750 | 03/04/22 |
Chen Richard | Chief Medical Office.. Chief Medical Officer | Mar 02 | Sell | 10.18 | 471 | 4,795 | 157,334 | 03/04/22 |
Tachibana Aaron | Chief Financial Offi.. Chief Financial Officer | Mar 02 | Sell | 10.18 | 4,511 | 45,922 | 251,441 | 03/04/22 |
Chen Richard | Chief Medical Office.. Chief Medical Officer | Jan 28 | Sell | 9.93 | 705 | 7,001 | 157,805 | 02/01/22 |
Tachibana Aaron | Chief Financial Offi.. Chief Financial Officer | Jan 28 | Sell | 9.93 | 705 | 7,001 | 255,952 | 02/01/22 |
West John Stephen | President and CEO President and CEO | Jan 18 | Sell | 11.37 | 99,987 | 1,136,852 | 285,457 | 01/19/22 |
West John Stephen | President and CEO President and CEO | Jul 12 | Sell | 22.54 | 110,000 | 2,479,400 | 635,520 | 07/12/21 |
West John Stephen | President and CEO President and CEO | Jun 10 | Sell | 22.66 | 110,000 | 2,492,600 | 560,520 | 06/10/21 |
Chen Richard | Chief Scientific Off.. Chief Scientific Officer | Dec 03 | Option | 0.44 | 40,000 | 17,600 | 152,750 | 12/03/20 |
Chen Richard | Chief Scientific Off.. Chief Scientific Officer | Dec 03 | Sell | 27.88 | 40,293 | 1,123,369 | 112,457 | 12/03/20 |
Abingworth LLP | 10% Owner 10% Owner | Oct 14 | Sell | 28.76 | 202,360 | 5,819,874 | 4,260,092 | 10/14/20 |
Chen Richard | Chief Scientific Off.. Chief Scientific Officer | Oct 05 | Option | 0.44 | 37,452 | 16,479 | 152,750 | 10/05/20 |
Chen Richard | Chief Scientific Off.. Chief Scientific Officer | Oct 05 | Sell | 21.97 | 40,000 | 878,800 | 112,750 | 10/05/20 |